Shares of Biogen and Ionis Pharmaceuticals were higher Monday after announcing that their treatment for a rare, children’s spine disorder had some positive results. The two companies said their treatment for infantile-onset spinal muscular atrophy demonstrated statistically significant improvement in certain motor functions, according to a Wall Street Journal report. Ionis shares jumped nearly 30
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
